An internal standard for the quantification of olsalazine
Related Products
Unlabeled Version(s)
23661Olsalazine (sodium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Olsalazine-13C6

Item No. 33798

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(E)-5-((3-carboxy-4-hydroxyphenyl)diazenyl)-2-hydroxybenzoic-1,2,3,4,5,6-13C6 acid
Molecular Formula
C8[13C]6H10N2O6
Formula Weight
308.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: solubleMethanol: soluble
SMILES
OC(C1=C(O)C=CC(/N=N/[13C]2=[13CH][13C](C(O)=O)=[13C](O)[13CH]=[13CH]2)=C1)=O
InChi Code
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+/i1+1,3+1,5+1,7+1,9+1,11+1
InChi Key
QQBDLJCYGRGAKP-FCGFREEASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $702

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine (Item No. 23661) by GC- or LC-MS. Olsalazine is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA; Item No. 70265) that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1 In vitro, olsalazine increases ion transport in isolated rabbit distal ileum when applied to the luminal side (ED50 = 0.3 mM) and stimulates fluid transport in rat jejunum when used at a concentration of 5 mM.2,3 Olsalazine (150 mg/kg for 8 days) improves stool consistency and decreases occult and gross bleeding as well as myeloperoxidase (MPO) activity and leukotriene B4 (LTB4; Item No. 20110) levels in colon tissue in a mouse model of acute colitis induced by dextran sulfate (Item No. 23250).4 Olsalazine also inhibits bovine xanthine oxidase in vitro (IC50 = 3.4 mg/L) and lowers serum uric acid levels in a mouse model of hyperuricemia induced by oxonic acid (Item No. 22586) when administered at a dose of 20 mg/kg.5 Formulations containing olsalazine have been used in the treatment of inflammatory bowel disease (IBD) and ulcerative colitis.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nugent, S.G., Kumar, D., Rampton, D.S., et al. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48(4), 571-577 (2001).

    2. Pamukcu, R., Hanauer, S.B., and Chang, E.B. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 95(4), 975-981 (1988).

    3. Mohsen, A.Q.M., Mulvey, D., Priddle, J.D., et al. Effects of olsalazine in the jejunum of the rat. Gut 28(3), 346-352 (1987).

    4. Murthy, S., Murthy, N.S., Coppola, D., et al. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis. Inflamm. Res. 46(6), 224-233 (1997).

    5. Niu, Y., Li, H., Gao, L., et al. Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity. J. Pharmacol. Sci. 135(3), 114-120 (2017).